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ABSTRACT
CHARACTERIZ!<TION OF DANAZOL
BINDING OF SPECIFIC
CYTOSOL RECEPTORS
IN VITRO
Gail Wright Russell, M. S.
Morehead State University, 1982
The binding of danazol to specific cytosol receptors
in• vitro was performed on uterine, mammary, adrenal,
pituitary and hypothalamic tissue, using the hydroxylapatite assay.

This study was designed to determine the

specificity of danazol binding to cytosol receptors,
evaluate danazol's dose responsiveness and determine the
ability of dahazol to translocate specific cytosol
receptors into the nucleus.

Results were obtained by

using radioactively tagged estradiol, dihydrotestosterone,
progesterone and corticosterone.
Danazol was shown to bind and translocate each
steroid receptor, though not significantly, while showing
the greatest success with the androgen receptor in all
tissues.

The dose responsiveness of danazol was effec-

tively demonstrated by its increased competition at
pharmacological concentrations.

Furthermore., the

results indicated that danazol was most effective in
translocating the androgen receptor in mammary tissue.
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INTRODUCTION
The intrace,llular mechanisms underlying steroid
regulation of target cells are not fully understood.
However, important events in the regulation appear to be
steroid entry into cells of the specific target tissue,
interaction of the steroid with its specific cytosol
receptor, and translocation of the steroid-receptor
complex to the cell nucleus.

Presumably this leads to

initiate messenger RNA (ribonucleic acid) and protein
synthesis (Figure 1).
An important factor in establishing. the current
understanding of the mechanism of steroid hormone action
was the synthesis of isotopically labeled compounds, they
provided the first molecular probes to discern the
sequence of events that occur following the interaction
of a steroid hormone with a target cell (Jensen and
Jacobson,1962).

The use of tritium ( 3 H) labeled compounds

has also become very prominent in estrogen receptor
studies involving breast cancer.
An increased incidence of new cases of breast cancer
annually in the United States and numbers of deaths due
to the disease has created a greater interest towards
studies evaluating estrogen receptors and their role in
treatment of malignant and benign tumors.
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Witliff (1977)
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Mechanism of action of steroid hormones.
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suggests that a tissue demonstrating estrogen receptors
should be classified as an estrogen target and should
require hormone for maintenance and growth.

Removal of

estrogen should result in regression or involution of the
tissue.

In contrast, tissue lacking estrogen receptors

should not be effected by removal of endogenous hormone.
The first evidence of a relationship between the association of 3 H hormones with a breast tumor and the clinical
response of the patient to ablative hormone therapy was
shown by Folca and associates in 1961 (Folca, Glascock,
and Irvine, 1961).

Other research also substantiates

Witliff's proposal showing that 25-40% of patients with
inoperable breast cancer have neoplasms that regress
after either the administration or pharmacological concentrations of hormones, such as androgens and estrogens,
or removal of endogenous hormones, such as by ovariectomy
or adrenalectomy (_Kennedy, 1974).

These findings suggest

that some malignant breast tumors may be hormone
dependent.
The concept underlying endocrine therapy is that
certain tumor cells have retained their ability to respond
to the same hormonal stimuli as their normal progenitor
cells (Witliff, 1977).

It is therefore suggested that

the presence of specific estrogen receptors in human
breast carcinomas may be predictive of a patient's
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response to endocrine therapy (Garola and McGuire, 1978,
Witliff, 1977, and McGuire, 1975).
Other steroid receptors are also present in human
breast cancer cells and may provide additional information.
For example, Horwitz et al (1975) predict that the presence of progesterone receptors in a tissue should be an
even more sensitive indicator of potential ·responsiveness
to endocrine therapy than the estrogen receptor.

The

basis for such a prediction is the underlying concept
that progesterone effects require estrogen priming,
thereby inducing the synthesis of the progesterone·
receptor (Figure 2).

r

llJRNA

Figure 2.

Induction of progesterone receptor by
estradiol (McGuire et al, 1978).
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Thus, the presence of progesterone receptors in a
tumor would indicate that the entire sequence, involving
estrogen binding to a cytoplasmic receptor, movement of
the receptor complex into the nucleus, and stimulation
of a specific end product, can be achieved in a tumor
cell.

This would rule out the existence of a defect be-

yond the binding step (McGuire -et al, 1978).

Therefore,

the presence of progesterone receptors in cancerous
tissue will show that the tumor remains under at least
partial endocrine control and may be classified as endocrine responsive.

In support of the prediction, research

showed 56% of tumors with estrogen receptors also had
progesterone receptors, and tumors without estrogen
receptors also lacked progesterone receptors lHorwitz
et al, 1975).

Preliminary data show only those breast

tumors with progesterone receptors regressed after
endocrine therapy.

Continuation of estrogen and pro~

gesterone receptor studies together with research directed
toward the evaluation of other steroid receptors present
in human breast carcinomas, such as androgens and glucocorticoids may give hope of treatment for those patients
with estrogen-receptor positive but unresponsive tumors.
In research by McGuire (19.771, it was shown in
randomly tested human breast tumors that 75% were
estrogen-receptor positive (ER+), with 74% of the ER+
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tumors also having progesterone receptors (PgR) and only
9% of the ER

tumors having PgR.

Where primary versus

metastatic tumors were examined, 77% of the primary
tumors were ER+ with 77% of them containing PgR and 66%
of the metastatic tumors with ER+ with only 59% of them
having PgR (Figure 3).
Danazol is an isoxazole derivative of the synthetic
steroid 17 a-ethinyltestosterone (Figure 4).

It acts

through the suppression of gonadal function (Chamness
et al, 1980), and may possibly be used in future treatment of hormonally dependent cancers, particularly those
of the breast and endometrium (Jenkin, 1980).

Support

for the use of danazol was strengthened by the reported
increased incidence of breast cancer in patients with a
history of benign breast diseases (Humphrey and Swerdlow,
1962, Davis• et al, 1964, Veronesi and Pizzocaro, 1968, and
Dmowski and Cohen, 1978), and the fact that danazol has
been shown to cause relief o_f various disorders of the
breast (Greenblatt· et al_, 1971, Lauersen and Wilson,
1976, Asch and Greenblatt, 1977, and Blackmore, 1977a).
The attempts to show differences between estrogen
receptors in normal human breast tissue and fibrocystic
tissue have thus far been unsuccessful (Terenius et al,
1974).

Randomly tested tumors

Metastatic Tumors

vs

A

(59%)PgR+

Figure 3.

(41%)PgR

(33%)ER-

0

(3%)PgR

(97%)PgR-

Summary of distribution of ER and PgR in human breast tumors (McGuire,
1977).

_,

8

c=cH
·-OH

Danazol
Figure 4.

Structure of Danazol.

However, Peters and Lewis (1976) showed that
dimethyl-1,2-benzanthracene (DMBA) induced mammary cancer
in rats was sensitive to danazol therapy.

They found

that danazol was effective in inhibiting carcinogenesis
when given before DMBA and, furthermore, caused regression
in established tumors.

The authors concluded from their

studies that danazol should be considered for clinical
trials in the treatment of breast cancer.
Danazol was synthesized at the Sterling-Winthrop
Research Institute by Manson and associates (1963), and
marketed as Danocrine.

In reference to danazol,

Sterling-Winthrop Laboratories makes the following
statement:

"Danazol suppresses the pituitary-ovarian

axis by inhibiting the output of gonadotropins from the
pituitary gland.

The only other demonstrable hormonal

effect is weak androgenic activity."

(Physicians Desk
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Reference, 1982).

Sterling-Winthrop suggests that, for as

long as danazol is administered, it suppresses luteinizing
hormone (LH) and follicle stimulating hormone (FSH)
release.

Without stimulation by these gonadotropins,

ovulation and the full production of estrogen is prevented
and thus, no corpus luteum or progesterone production
occurs (Jenkin, 1980).

Thus, danazol's therapeutic use

would be advised for those patients in whom runenorrhea,
suppression of gonadal steroids or inhibition of pituitary
gonadotropin was expected to be beneficial.

Accordingly,

the widest clinical application for danazol has been in
treatment of endometriosis (Dmowski, 1979, Dmowski and
Cohen, 1978 and Greenblatt et .al, 1971) where it alters
.

normal and ectopic endometrial tissue, so it becomes
inactive and atropic (Physicians Desk Reference, 1982).
In benign breast disease, particularly fibrocystic
disease, danazol usually produces partial to complete
disappearance of nodularity.

Due to danazol's suppression

of the hypothalamic-pituitary axis, anovulation and thus
ammenorrhea result.

However, cyclic bleeding usually

returns within 60-90 days (Physicians Desk Reference,
1982).
The androge'nici ty of the drug has been evident in the
few side effects demonstrated.

Weight gain was common,

with relatively few patients showing mild hirsutism, acne
or skin oiliness (Greenblatt et al, 1971).
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In recent studies, danazol has been demonstrated to
have four major pharmacologic effects:

(1) direct

inhibition of gonadotropin synthesis and/or release
(Lauersen and Wilson, 1977, Wood et al, 1975, and
Eldridge, Dmowski and Mahesh, 1974);

(2) direct inhibition

of multiple enzymes of steroidogenesis (Barbieri et al,
1977, and Barbieri, Camick and Ryan, 1977);

(3) inter-

action with androgen, glucocorticoid and progesterone
receptors in target tissues (Barbieri, Lee and Ryan, 1979,
and Chamness, Asch and Pauerstein, 1980); and (4) alter~
ation of endogenous steroid metabolism (Barbieri, Lee and
Ryan, 1979, and Barbieri and Ryan, 1981).

The majority

of studies exclude binding to the estrogen receptor as a
possible method of action (Krey, Robbins and McEwen, 1981,
Chamness, Asch and Pauerstein, 1980, Barbieri et al, 1979,
Creange, Potts and Schane, _1979, Woods et al·, 1975,
Dmowski et al, 1971, and Potts et al, 1974).
In further examination of danazol's antigonadotropic
action, Chamness, Asch and Pauerstein (1980) studied its
ability to bind and translocate androgen, estrogen and
progesterone receptors both in vivo and in Vitro in the
rat.

Their results showed danazol bound to the proges-

terone and androgen receptors, however, only the androgen
receptor was translocated to the nucl~us at effective
antigonadotropic doses.
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To further understand the mechanism of danazol's
action in its target cells, the following study was performed to (1) determine the specificity of danazol
binding to cytosol receptors by competitive binding
experiments,

(2) evaluate the dose response relationship

of danazol; and (3) to determine the specificity for
danazol to translocate receptors into the nucleus.

MATERIALS AND METHODS
Animal Care
Nineteen Sprague-Dawley female rats ranging 200-225
grams in weight, were obtained from Harlan Industries,
Indianapolis, Indiana.

Prior to being sacrificed, they

were maintained for two weeks in animal quarters on
Purina Lab Chow (Ralston-Purina Co.) and tap water ad
libitum.
Tissue Preparation
The rats were stunned, decapitated, exsanguated and
five tissues (uterus, mammary adrenals, hypothalamus and
pituitary) were removed from each.

Immediately upon

excision, each tissue was placed on a chilled glass
plate, trimmed of excess fat with a razor blade, weighed
and quick frozen in dry ice and acetone.

Each tissue was

wrapped individually in foil, labeled and stored in a
freezer for future competitive binding and dose-response
experiments.
For in vitro nuclear translocation experiments,
uteri from fourteen pre-puberal and thirteen post-puberal
Sprague-Dawley rats were excised using the same method as
mentioned above.

After being trimmed of excess fat, the

uteri were incubated in media consisting of 1 ml mimimal

12

13

essential media with Earle's salts and L-glutamine
(Grand Island Biological Co.) and l ml of Kreb's Ringer
Bicarbonate Glucose, pH 7.4 (Urnbreit et al, 1964).

Forty

microliters of indicated steroids in 100% ethanol were
added to give a final concentration of 2 x 10-B Mand the
uteri were incubated for two hours at 37°c with gentle
bubbling of 95% osygen:

5% carbon dioxide in a Dubnoff

Metabolic Shaking Incubator (GCA Precision Scientific).
Controls were incubated with 100% ethanol.

After incu-

bation, the tissue was blotted, weighed and quick frozen
in dry ice and acetone for later assay.
Isolation of Cytoso'l and Nuclear Recep·tors
All procedures were done on ice and/or in a
refrigeration unit at 4°c, unless specified otherwise.
Centrifugations were carried out (depending on the procedure, sample size and rpm specification) in either a
Beckman "Airfuge", International Refrigerated Centrifuge,
Model B-20 (International Equipment Co.) or an Adams
Sero-fuge.

Where microliter volumes were required,

automatic micro-pipets (Oxford laboratories) were used.
Isolated cytosol and nuclear receptors were prepared
by a modification of the methods of Williams and Gorski
(1974), Chamness ·et al (1979), and Pavlik and Coulson
(1976).

Frozen tissue was cut into small pieces and then

homogenized in phosphate buffer [P-buffer (5rnM sodium
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phosphate, pH 7.4, lmM thioglycerol, 10% glycerol)] in
a seven milliliter Ten Broeck pyrex glass-glass tissue
grinder (about 100-150 mg tissue/ml P-buffer).

The

homogenate was centrifuged (Adams Sero-fuge) eight
minutes at 1000 x g; the supernatant was taken as the
cytosol, while the pellet was resuspended in P-buffer
and recentrifuged twice, then resuspended for one hour
in buffer with 0.4 M potassium chloride to extract
receptors from the nuclei.

The pellet was then centri-

fuged for 10 minutes at 2000 x g (International
Refrigerated Centrifuge) and the supernatant was assayed
for nuclear receptors.
Receptor Incubations
Duplicate 200 µl aliquots of cytosol or nuclear
extract were added to 50 µl of radioactive ligand, while
another duplicate 200 µl aliquots were added to 50 µl of
the same ligand with an excess of non-radioactive
competitors for determination of non-specific binding.
In addition, to measure total counts, duplicate 200 µl
aliquots of P-buffer were added to 50 µl of radioactive
ligand.

Final concentrations of radioactive ligands
-10

M [2,4,6,7,16,173
-10
H(N)] estradiol (137.1 Ci/mmole), 5 x 10
M [1,2,4,5,
(New England Nuclear) were 5 x 10

6,7,16,17- 3 H(N)] dihydrotestosterone (179.0 Ci/mmole),
5 x 10-lO M [1,2,6,7- 3 H(N)] progesterone (101.0 Ci/mmole),

15

5 x 10

-10

3

M [1,2,6,7- H(N)] corticosterone (105.0

Ci/mmole).

Non-radioactive competitors were 1.67 x 10- 7

M diethylstibesterol, 1.67 x 10- 7 M dihydrotestosterone,

1.67 x 10- 7 M progesterone, and 1.67 x 10- 7 M
corticosterone (all are final concentrations).

Incu-

bations for cytoplasmic receptors were all three hours
at

o0 c,

while those for nuclear receptors were three

hours at 30°c (estrogen) or 18 hours at
progestins and corticosteroids).

o0 c

(androgens,

Cytosol and nuclear

extract were saved (50 µl samples) for protein
determinations.
Binding Competition Experiments
Cytosol was prepared in P-buffer from uteri, mammary,
adrenal, hypothalamic and pituitary tissue (assayed
separately).

Duplicate aliquots of 200 µl of cytosol

were incubated with 50 µl of radioactive steroid in
buffer plus 50 µl of varying concentrations of danazol.
The danazol (Danocrine) was a gift from Sterling-Winthrop
Research Institute.

Binding was assayed by the hydro-

xylapatite method (HAP) and non-specific binding was
subtracted.
Dose Response Experiments
Cytosol was prepared in P-buffer from uterine
tissue.

Triplicate aliquots of 200 µl of cytosol were
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incubated with 50 µl of varying concentrations of
radioactive ligand.

Competitive binding was checked

with 50 µl of non-radioactive ligand added to one aliquot.
In addition, triplicate aliquots of 50 µl of radioactive
ligand were incubated with varying microliter concentrations of cytosol, with 50 µl of non-radioactive
competitor in one aliquot to check competitive binding.
Assay for binding was by the HAP method and non-specific
binding was subtracted.
Nuclear Translocation Experiments
Nuclear extract was prepared in P-buffer from uteri
of pre- and post-puberal rats.

In experiments with the

pre-puberal uteri, triplicate 200 µl aliquots of the
nuclear extract ·from control, d_anazol and dihydrotestosterone (DHT) incubated tissues were added to 50
µl aliquots of radioactive DHT with a triplicate also
containing 50 µl of non-radioactive DHT.
Post-puberal uterine experiment~ were performed,
using triplicate 200 µl aliquots of the nuclear extract
from control, danazol, DHT, progesterone, corticosterone
and estradiol incubated uteri, with a 50 µl aliquot of
appropriate radioactive ligand.

To check for competitive

binding a triplicate aliquot of 200 µl nuclear extract
from each incubation with 50 µl of radioactive steroid
plus 50 µl of non-radioactive competitor was performed.
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Hydroxylapatite Assay
One milliliter of hydroxylapatite suspension
[2.5 grams of Bio-Rad HTP, DNA grade, per 100 ml of TP
buffer (50 mM Tris and 10 mM KH Po )J was added to each
2 4
tube at the end of incubation and kept suspended by
occasional vortexing (Fisher Scientific Vortex-Genie)
for 30 minutes.

Th.e HAP was then centrifuged 1. 5 minutes

at 1000 x g, resuspended in 1.5 ml of fresh P-buffer, and
recentrifuged; this wash was completed twice more.

One

milliliter of 100% ethanol was then added to each pellet
to extract the radioactive steroid, which was then counted
in 5 ml of scintillation fluid (19 gm PPO and 1.9 gm
POPOP/3.8 L toluene}.

All counts were made in a Hewlett-

Packard Tri-Carb 300 scintillation counter at Maxey ilats
Low-Level Nuclear Waste Disposal Site.
Protein Assay
Protein concentrations were determined by a modification of the Lowry Method (Lowry et al, 1951).

To

precipitate proteins, cold 10% trichloroacetic acid was
added to 50 µl of cytosol or nuclear extract in a
cellulose nitrate tube (Beckman, 175 µl capacity) and
centrifuged in a Beckman Airfuge at 20 psi for 5 minutes.
The supernatant was aspirated with a disposable transfer
pipet.

To the protein precipitate, 100 µl of 3N sodium

hydroxide was added, stirred with a toothpick and set
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aside for 10 minutes.

Two concentrations (10 µland

50 µl) of the protein mixture and of a bovine serum
albumin standard (1 gm/ml) were added to separate test
tubes and brought to 0.5 ml with distilled water.

The

remaining procedures were identical with those of Lowry
et al (1951).

Measurement of protein concentrations

were made in a Bausch and Lomb Spectronic 70, and protein
was expressed in mg/ml.
Statistical· Analysis
Data were analyzed using the Student's t

test.

RESULTS
To evaluate the validity of the HAP assay and to
determine conditions to be used in later experiments,
titration curves were run for both
cytosol.

3

.

H-estradiol and

Specific activity was measured in counts per

minute/mg of protein.

Figure five shows a dose-response
relationship when the concentration of 3H-estradiol was
reduced in the incubate, in the presence of 200 µl of
cytosol.

Likewise, by the condition of increasing

amounts of cytosol, the expected dose relationship was
seen in specific activity.

This indicates as the cytosol

was increased, the amounts of cytosol receptors were
increased, therefore the increase in specific binding.
From these data, experimental protocol for all succeeding
experiments called for the use of 10- 9 M estradiol and
200 µl cytosol.
In the first series of experiments performed, the
competition for steroid receptors with increasing doses
of danazol were performed in various tissues.

The

results of these experiments are shown in figures six,
seven, eight and table one, and are expressed as a
percent of control binding.

In all experiments, danazol

exhibited a dose-response competition with steroid
receptors.

Figure six shows that in mammary tissue,

competition with the androgen ;receptor exceeded a,11
19
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other steroid receptors.

Binding was 58% of the control

at the physiological concentration of 10- 9 M danazol
compared to 88% of the control values of estradiol.
Danazol was the most efficient competitor of the androgen
receptor in uterine tissue, with a value of 80% of the
control at 10-

9

M (Figure 7).

The competition for

steroid receptors in pooled adrenal tissue is shown in
figure eight.

This figure shows poor competition with

all steroid receptors at 10

-9

M danazol and strong

competition at the pharmacological dose of 10-S M.
Due to the lack of cytosol for hypothalamic tissues,
only two assays were performed.
dose of 10

-9

Using only the test

M, results show in table one that danazol

competed most effectively with the DHT receptor (73% of
control) followed by progesterone (86%), corticosterone
(90%) and estradiol (91%).

Table 1.

Danazol competition for steroid receptors in
hypothalamic tissue.

Incubation conditions

Danazol (10

-9 M).

Estradiol

91*

DHT Progesterone

73

86,

Corticosterone

90

*Mean percent of cytosol alone which was taken as 100%.
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A single test was performed with pooled pituitary
cytosol, showing that danazol at 10-

9

M did compete with

the DHT receptor (65% of control).
A comparison of steroid binding competition by
danazol at 10- 9 Mis seen in table two.

This table

summerizes the data that danazol competes more favorably
with the androgen receptor in all tissues with a mean of
76% of the control followed by estradiol (91%),
progesterone (92%), and corticosterone (95%).
In vitro translocation experiments of steroid cytosol
receptors were performed to better determine receptor
specificity and biological function.

The first experi-

ments were performed on 25 day old, pre-puberal uterine
tissue and the results are shown in table three.
Compared to the control specific activity of 426 cpm/mg
protein, incubation with 10-

9

M DHT resulted in a 146%

increase over the control with a mean specific activity
-6
M transof 1050 cpm/mg protein (P<.l). Danazol at 10
located the androgen receptor 85% over the control.
In all experiments in which in vitro translocation
was evaluated in adult uterine tissue, danazol did not
signficantly elevate nuclear receptors in any of the
steroids tested (Table 4).

Danazol translocated the DHT

receptor most successfully with a value of 68% increase
over the control.

Incubation with respective steroids

Table 2.

Comparison of steroid binding competition by danazol at 10

Competing
Steroid Receptors

Uterus

Mammary

Adrenal

-9

M.

Hypothalamus

Mean

Estradiol

92*

87

92

91

91

DHT

80

58

93

73

76

Progesterone

89

95

98

86

92

Corticosterone

95

98

96

90

95

*Mean percent of control binding.
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Table 3.

In vitro translocation of uterine androgen
receptor in pre-puberal rats.

Treatment
N=6

Specific activity
cpm/mg protein

Control
DHT (10-g M)
Danazol (10- 6 M)

426±146*
1050±762~
790±483

*Mean± standard deviation
a

P<.1 from controls

Percent increase
over control

146
85
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Table 4.

In vitro translocation of uterine steroid
receptors in adult rats.

Treatment
N=6

Specific activity
cpm/mg protein

Estradiol

873±200*
1983±393a

Danazol

1041±491

Control

DHT

349±316
971±354b

Danazol

585±692

Control

570±370

Control

Percent increase
over control

127
19

178
68

1229±789

116

Danazol

694±528

22

Control

62±74

Corticosterone

95±47

53

Danazol

68±64

10

Progesterone

*Mean± standard deviation
a P<.001 from control
b P<.05

from control
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demonstrated that the cytosol receptor was translocated,
reflecting values that were significant for DHT (P<.05)
and highly significant for estradiol (P<.001).

DISCUSSION
The mechanism of action of danazol at the subcellular level is not completely understood.

However,

according to current ideas of hormone action, danazol
should bind to a specific cytosol receptor and translocate i t to the nucleus of that particular target cell,
where i t would initiate protein synthesis.
well

It has been

substantiated that danazol binds most efficiently

to the androgen receptor in various target tissues
(Chamness et al, 1980 and Barbieri et al, 1979).

It is

also suggested that danazol has a somewhat lower affinity
for the progesterone (Chamness et al, 1980 and Barbieri
et al, 1979) and glucocorticoid receptor (Barbieri et al,
1979), with little or no binding to the estrogen
receptor (Krey ·et al, 1981, Chamness et al, 1980, Woods
et al, 1975, Creange et al, 1979, Dmowski et al, 1971 and
Potts et al, 1974).

Results. of
this study
are concurrent
'
.

with these findings except for demonstrating a low
affinity binding of danazol to the estrogen receptor.
support of these data, Creange· et al,· (1979) has shown
danazol competition with estrogen receptors of the
pituitary.
At physiological doses, danazol competed similarly
with the estrogen, progesterone and glucocorticoid
30
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receptor, showing a somewhat better competition with the
androgen receptor (.Table 21.

In comparison, as

concentrations of danazol were increased, there was an
increased competition for all receptors (Figures 6,
7, and 8) .
To check for receptor specificity and biological
function, in vitro translocation experiments were performed on pre- and post-puberal rats.· Tn: · ~ experiments by Chamness ·et ·al (19.801 provides evidence that
the androgen receptor is the only one effectively translocated to the nucleus by danazol.

The findings of this

research, in contrast, show a non-statistical tendency
of danazol translocating the androgen receptor in
pre-puberal and adult rats (.Table 3 and 4) along with. a
somewhat lesser ability to translocate the estrogen,
progesterone and. glucocorticoid receptor (Table 4).•
It is generally agreed that danazol has weak
androgenic and no estrogenic or anti-estrogenic properties, while its glucocorticoid and progestational
effects are still somewhat controversial (Dmowski, 1979,
Barbieri, et al, 1979, Dmowski et al, 1971 and Potts· et ·a1,
1974)..

Therefore, it must b.e concluded from this study

that the strong binding and translocation of the androgen
receptor by danazol is indicative of its androgenic
responses elicited in vivo.

The lower binding affinity
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for the estrogen, progesterone and. glucocorticoid
receptor and subsequent translocation of these receptors
may suggest the action of danazol on these receptors is
not sufficient to stimulate mRNA synthesis and thus
biological activity.
Difficulty in obtaining good specific binding
counts was a drawback of this procedure,

It is sug-

gested that higher counts may be obtained by a wash
buffer of 1% Tween 80 in phosphate buffer, which has been
shown to be more successful at diminishing the nonspecific binding (Garola and McGuire, 1978) than
phosphate buffer alone.
In summary, evidence presented in this research
indicates that danazol binds to and translocates estrogen,
progesterone, glucocorticoid and androgen receptors in
vitro, though not significantly, while showing the
greatest success with the androgen receptor in all
tissues.

The dose responsiveness of danazol was

effectively demonstrated by its increased competition at
pharmacological concentrations.

Furthermore, the

results indicated that danazol was most effective in
translocating the androgen receptor in mammary tissue.
In light of this research, as well as evidence
reported in the literature, the evaluation of receptor
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bindi11g and nuclear translocation data, will hopefully
lead to a better understanding of normal steroid target
cells, cancer modified cells and drug interaction with
each cell type.
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